

## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

Claims 1-28 (Canceled).

Claim 29 (Currently Amended): A method of using a composition, for the preparation of a drug for the ~~prevention and/or~~ treatment of the psychiatric disturbances of the central nervous system (CNS) selected from the group consisting of schizophrenia, manic-depressive syndrome, major depression, and Alzheimer's disease comprising a component selected from the group consisting of

a) alpha-linolenic acid (ALA, C18:3 n-3) and/or the pharmaceutically acceptable derivatives and/or precursors thereof;

b) docosahexaenoic acid (DHA, C22:6 n-3) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; and

c) DHA in admixture with eicosapentaenoic acid (EPA, C20:5 n-3), in a ratio of 1:0.5 to 1: 1.7, respectively, and/or the pharmaceutically acceptable derivatives and/or precursors thereof;

wherein said component is present in a concentration not lower than 70% by weight of the total fatty acids weight in the composition;

with the provisos that:

when the composition comprises b), arachidonic acid is not added thereto; and

when the composition comprises c), it does not comprise 10 to 40% by weight of reducing/antioxidant vitamins or provitamins.

Claim 30 (Currently Amended): The method according to claim 29, wherein schizophrenia shows ~~negative and/or~~ positive symptoms.

Claim 31 (Currently Amended): The method according to claim 29, wherein schizophrenia is paranoid, ~~catatonic, disorganised or undifferentiated~~ schizophrenia.

Claim 32 (Withdrawn): The method according to claim 29, wherein the manic-depressive syndrome and major depression include disorders of mood, behaviour and autonomic functions correlated to activity, sleep and appetite.

Claim 33 (Withdrawn): The method according to claim 29, wherein the Alzheimer's disease includes the various related forms of dementia.

Claim 34 (Previously Presented): The method according to claim 29, wherein the ratio of DHA to EPA in c) is of 1:0.9 to 1:1.5.

Claim 35 (Previously Presented): The method according to claim 29, wherein the concentration of either. a) or b) or c) is of 75% to 95% by weight of the total fatty acids weight in the composition.

Claim 36 (Previously Presented): The method according to claim 29, wherein the concentration of either a) or b) or c) is of 80% to 90% by weight of the total fatty acids weight in the composition.

Claim 37 (Previously Presented): The method according to claim 29, wherein the concentration of either a) or b) or c) is of 85% by weight of the total fatty acids weight in the composition.

Claim 38 (Previously Presented): The method according to claim 29, wherein the composition comprises at least one other n-3 and/or n-6 polyunsaturated and/or monounsaturated and/or saturated fatty acid.

Claim 39 (Previously Presented): The method according to claim 38, wherein the composition comprises at least two other n-3 and/or n-6 polyunsaturated and/or monounsaturated and/or saturated fatty acids, in any ratio among themselves.

Claim 40 (Previously Presented): The method according to claim 38, wherein the other n-3 and/or n-6 polyunsaturated and/or monounsaturated and/or saturated fatty acids are in a concentration of lower than or equal to 30%.

Claim 41 (Previously Presented): The method according to claim 29, wherein the derivatives of ALA, DHA and EPA are selected from the group consisting of their C.sub.1-C.sub.3 alkyl esters, glyceride mono-, and di-tri-esters, salts with pharmaceutically acceptable bases, and the

precursors of ALA, DHA and EPA are compounds able to lead to them through in vivo transformations.

Claim 42 (Previously Presented): The method according to claim 29, wherein the drug comprises essentially DHA ethyl ester and EPA ethyl ester.

Claim 43 (Previously Presented): The method according to claim 29, wherein the drug is administered by oral route.

Claim 44 (Previously Presented): The method according to claim 29, wherein the drug is in the form of soft gelatine capsules.

Claim 45 (Previously Presented): The method according to claim 29, wherein the drug is administered at the dose of 0.1-5 g/day.

Claim 46 (Previously Presented): The method according to claim 29, wherein the drug is administered at the dose of 0.3-3 g/day.

Claim 47 (Previously Presented): The method according to claim 29, wherein the drug is administered at the dose of 1-2 g/day.

Claim 48 (Previously Presented): The method according to claim 29, wherein the drug is administered separately, as a coadjutant or an auxiliary drug, from at least another drug effective for the prevention and/or treatment of the disturbances of CNS.

Claim 49 (Previously Presented): The method according to claim 29, wherein the drug comprises at least another drug effective for the prevention and/or treatment of the disturbances of CNS.